LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Research

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome)

Burza S, Mahajan R, Singh A, van Griensven J, Pandey K, Lima MA, Sanz MG, Sunyoto T, Mitra G, Kumar R, Verma N, Das P
Download
Download
Abstract
Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this region. A 2011 observational cohort study conducted in Bihar involving 55 VL/HIV co-infected patients treated with 20-25 mg/kg intravenous liposomal amphotericin B (AmBisome) estimated an 85.5% probability of survival and a 26.5% probability of VL relapse within 2 years. Here we report the long-term field outcomes of a larger cohort of co-infected patients treated with this regimen between 2007 and 2012.
Countries
India
Subject Area
neglected tropical diseaseskala azarHIV/AIDS
DOI
10.1371/journal.pntd.0003053
Published Date
07-Aug-2014
Languages
English
Journal
PLOS Neglected Tropical Diseases
Volume / Issue / Pages
Volume 8, Issue 8, Pages e3053
Issue Date
07-Aug-2014
Dimensions Badge